Plain-English translation of NCT04339764 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new surgical treatment that uses your own cells to help fight geographic atrophy, an advanced form of dry age-related macular degeneration (AMD) that causes progressive vision loss. Researchers will take some of your cells, reprogram them into stem cells, grow them into eye tissue called retinal pigment epithelium (RPE) in a laboratory, and then surgically transplant this tissue back into your eye. The goal is to stop the vision loss and potentially help restore some of your sight.
Geographic atrophy is a serious condition that causes the light-sensitive cells in the back of the eye to gradually die, leading to blindness. Currently, there are very few treatment options available, so this trial exists to see whether a personalized stem cell transplant can offer hope to patients who have limited other choices.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will undergo outpatient eye surgery to receive the stem cell transplant into one eye. Before surgery, researchers will take a small sample of your skin cells to create your personalized stem cells in the laboratory, which typically takes several months. After your transplant surgery, you will have regular follow-up visits over at least 12 months to monitor your vision, eye health, and any side effects. The study will track whether the transplant is safe and whether it helps improve or stabilize your vision.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States